Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Daniel J. Lippis sold 857 shares of the company's stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $85.60, for a total value of $73,359.20. Following the completion of the sale, the vice president now directly owns 23,890 shares in the company, valued at approximately $2,044,984. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Edwards Lifesciences Stock Up 0.3 %
NYSE EW traded up $0.26 during mid-day trading on Friday, reaching $87.68. 224,645 shares of the company's stock traded hands, compared to its average volume of 3,670,507. The company has a fifty day simple moving average of $90.03 and a 200-day simple moving average of $79.73. Edwards Lifesciences Co. has a 1-year low of $60.57 and a 1-year high of $96.12. The company has a market cap of $52.84 billion, a price-to-earnings ratio of 37.68, a P/E/G ratio of 3.59 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.
Institutional Trading of Edwards Lifesciences
The ONE AI Stock to own now. (It’s not Nvidia.)
From Weiss Ratings | Ad
Don’t panic — you haven’t missed the boat on AI.
In fact, it has barely launched.
Sure, the early stages of this boom were big …
But I believe the real wealth in AI has yet to be made …
Click here to see the presentation now.
Institutional investors and hedge funds have recently modified their holdings of the business. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the fourth quarter valued at $34,000. Riverview Trust Co acquired a new position in shares of Edwards Lifesciences during the first quarter valued at $34,000. Pingora Partners LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter worth about $38,000. Finally, Operose Advisors LLC increased its holdings in shares of Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company's stock worth $44,000 after acquiring an additional 452 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
EW has been the subject of a number of recent research reports. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an "overweight" rating in a research report on Friday, April 26th. Barclays raised their target price on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the stock an "overweight" rating in a research report on Tuesday. Citigroup boosted their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a report on Wednesday, April 3rd. Piper Sandler lifted their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company a "neutral" rating in a research report on Friday, April 26th. Finally, OTR Global raised Edwards Lifesciences from a "mixed" rating to a "positive" rating in a research note on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $93.27.
Get Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Company Profile
(
Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
